Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy

Summary

The aim of this clinical trial is to evaluate the efficacy and safety of the WST09-mediated vascular-targeted photodynamic therapy (VTP) in patients with localized prostate cancer recurrent after external radiation therapy or temporary (High Dose Rate, or HDR) brachytherapy.

Timeline

Start

2006-05

Primary completion

2008-07

Completion

2009-12

Outcome

Outcome not reported

Stopped: “STEBA decided to develop WST11 that is soluble in aqueous solutions. The property of WST 11 make it safer and better candidate for therapeutic applications.”

Drugs

Indications